AstraZeneca antibody therapy prevents COVID-19 in trial, company says
AstraZeneca released Phase 3 data showing promising results for a combination antibody therapy that prevents infectious-disease, possibly opening the door to an alternative option for people who may not see the full protective benefits from the currently authorized infectious-disease. The PROVENT pre-exposure prophylaxis trial showed AZD7442 reduced the risk of developing symptomatic COVID-19 by up…